The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Tempest Therapeutics Inc (NASDAQ: TPST) closed at $1.85 up 8.82% from its previous closing price of $1.70. In other words, the price has increased by $8.82 from its previous closing price. On the day, 0.82 million shares were traded. TPST stock price reached its highest trading level at $1.87 during the session, while it also had its lowest trading level at $1.66.
Ratios:
For a deeper understanding of Tempest Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.13 and its Current Ratio is at 3.13. In the meantime, Its Debt-to-Equity ratio is 0.99 whereas as Long-Term Debt/Eq ratio is at 0.63.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 14, 2024, initiated with a Sector Outperform rating and assigned the stock a target price of $13.
On February 08, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 03 ’24 when Brady Stephen R bought 35,000 shares for $2.11 per share. The transaction valued at 73,850 led to the insider holds 46,376 shares of the business.
Whiting Samuel bought 4,672 shares of TPST for $9,951 on Jul 02 ’24. The Chief Medical Officer now owns 9,573 shares after completing the transaction at $2.13 per share. On Jun 28 ’24, another insider, Trojanowski Justin, who serves as the Corporate Controller of the company, bought 7,500 shares for $2.16 each. As a result, the insider paid 16,200 and bolstered with 22,168 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TPST now has a Market Capitalization of 41102004 and an Enterprise Value of 29146940.
Stock Price History:
Over the past 52 weeks, TPST has reached a high of $9.77, while it has fallen to a 52-week low of $0.17. The 50-Day Moving Average of the stock is -28.82%, while the 200-Day Moving Average is calculated to be -48.11%.
Shares Statistics:
For the past three months, TPST has traded an average of 985.69K shares per day and 510920 over the past ten days. A total of 22.05M shares are outstanding, with a floating share count of 17.41M. Insiders hold about 21.64% of the company’s shares, while institutions hold 6.28% stake in the company. Shares short for TPST as of 1721001600 were 1944149 with a Short Ratio of 1.97, compared to 1718323200 on 1608077. Therefore, it implies a Short% of Shares Outstanding of 1944149 and a Short% of Float of 10.86.
